Indoco Remedies Ltd (INDOCO) — Announcement | 10 September 2026
Indoco Remedies disclosed that the UK MHRA completed a cGMP inspection of its Goa-based Plant I facility from September 7-9, 2026, with no critical or major observations, confirming compliance with global quality standards and supporting its international business contribution of approximately 30%.
About Indoco Remedies Ltd (INDOCO)
Healthcare · Pharmaceuticals · Listed on BSE
📡 Get AI alerts when INDOCO files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track INDOCO — Free💡 Ask AI about this filing
📊 More INDOCO filings
- Announcement — 29 September 2026Indoco Remedies Ltd has sent a mandatory notice to physical shareholders requiring PAN, KYC, and ban...
- 🔴 Corporate Action — 28 September 2026Indoco Remedies announced incorporation of wholly owned subsidiary Warren Lifesciences Private Limit...
- Announcement — 28 September 2026Indoco Remedies Ltd announced the closure of its trading window effective October 1, 2026, until 48 ...
- 🔴 Announcement — 24 September 2026Indoco Remedies informed stock exchanges that Crisil ESG Ratings & Analytics assigned an ESG rating ...
- 🟡 Voting Results — 18 September 2026Indoco Remedies shareholders approved all 9 AGM resolutions via electronic voting on September 17, 2...
🔥 Also filed on 10 September 2026
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when INDOCO files new disclosures
Track INDOCO filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track INDOCO — FreeFree account · 2 AI queries/day